Skip to Content
COVID-19 Resources
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 05/06/20

John (Torrey) Sandlund, MD


John (Torrey) Sandlund, MD, an internationally recognized expert in the development of new therapies for pediatric lymphomas, joined the Investigational Drug Branch (IDB) in April 2020. His research career has focused on defining clinical, pathological, and molecular subtypes of non-Hodgkin lymphoma and instituting clinical trials directed at these different subtypes. In IDB, he will focus on tyrosine kinase inhibitors and downstream MAPK pathway inhibitors, protein homeostasis inhibitors, and epigenetic agents.

Dr. Sandlund earned his undergraduate and doctoral degrees at The Ohio State University, performed his residency at Columbus Children’s Hospital, and his oncology fellowship in the Pediatric Oncology Branch, NCI. He has spent his entire professional career at St Jude Children’s Research Hospital, rising from Assistant Member to Full Member and serving in several leadership positions at that institution, most notably serving as clinical director for the leukemia/lymphoma inpatient unit and clinic for many years. Dr. Sandlund is an author or co-author of over 200 scholarly publications, including clinical research papers, book chapters, and reviews.

About the Branch Chief

Jeffrey A. Moscow, MD Jeffrey A. Moscow, MD, joined the Investigational Drug Branch (IDB) in 2014 after serving part time since 2012, and was appointed Branch Chief in 2018. He is a graduate of Harvard University and the Geisel School of Medicine at Dartmouth. Dr. Moscow completed his pediatric residency at the University of Texas Southwestern in Dallas and a fellowship in pediatric hematology-oncology in the Pediatric Oncology Branch, NCI. More…